课题基金 / 基金详情

Expression of Somatostatin-Receptor and Inhibitory Effect of Somatostatin on Cell Proliferation in Hepatobiliary Malignancies

Expression of Somatostatin-Receptor and Inhibitory Effect of Somatostatin on Cell Proliferation in Hepatobiliary Malignancies
生长抑素受体在肝胆肿瘤中的表达及其对细胞增殖的抑制作用
批准号:
10671156
负责人:
MIYAZAKI Masaru
金额:
$2.43万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

MIYAZAKI Masaru的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To evaluate the possibility of Somatostatin therapy for hepatobiliary tumors, molecular biological approaches were performed using MIN 6-cultured tumor cells in vitro. Cell proliferation was assessed by MTT assay, and mRNA expression of c-fos and c-jun by northern blotting and expression of Somatostatin receptor of hepatobiliary tumors by RT-PCR method. Our studies revealed the expression of Somatostatin receptor in MIN6 cells. It was shown that the proliferative activity of MIN6 cells was inhibited with the addition of Somatostatin into culture media. Furthermore, the expression of c-fos in MIN6 cells stimulated by serum was significantly suppressed by the pretreatment with Somatostatin. The expression of Somatostatin receptor was investigated in hepatobiliary tumors which were obtained as surgical specimen ; bile duct cancers in three, gallbladder carcinoma in one, hepatic cholangiocarcinoma in one. All these tumors were demonstrated to express only SSTR2, a subtype of Somatostatin r … More eceptor. Somatostatin was revealed to have inhibitory effects on cell proliferation through the mechanism that Somatostatin regulates the rate of cell proliferation by G-protein mediated signal transduction in MIN6 cells. The fact that hepatobiliary tumors have been shown to prossess Somatostatin receptor subtype, SSTR2, might suggest therapeutic implication of Somatostatin for hepatobiliary malignancies in clinical practice. It should be required to clarify the clinocopathological relationship between the expression of Somatostatin receptor and the various steps of tumor growth in hepatobiliary malignancies for the clinical application of Somatostatin therapy. At present, we are investigating its relationship using enough surgical samples including metastatic lymphnodes of hepatobiliary malignancies obtained in our institution. Our analysis has been clarifying how the expression of Somatostatin receptor affects biological events at molecular level of tumor invasion and metastasis in hepatobiliary malignancies. Therefore, further extensive investigations of this project should be required. Less
期刊论文(20)
专著(0)
科研奖励(0)
会议论文
Masaru Miyazaki: "Parenchyma preserving hepatectomy in the surgical treatment of hilar chalangiocarcinoma"Journal of American College of Surgeons. 189・6. 575-583 (1999)
Masaru Miyazaki:“保留肝实质的肝切除术治疗肝门胆管癌”,美国外科医师学会杂志 189・6(1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
M MIYAZAKI: "Aggressive surgical approaches to hilar cholangiocarcinoma ; Hepatic or local resection?"Surgery. 123. 131-136 (1998)
M MIYAZAKI:“肝门部胆管癌的积极手术方法;肝切除术或局部切除术?”手术。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Miyazaki M et al: "Segments I and IV resection as a new approach for hepatic hilar cholangiocarcinoma" American Journal of Surgery. 175. 229-231 (1998)
Miyazaki M 等人:“I 段和 IV 段切除作为肝门部胆管癌的新方法”美国外科杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masaru Miyazaki: "Aggeressive surgical approaches to hilar cholangiocarcinoma Hepatic or local resection?"Surgery. 123・2. 131-136 (1998)
宫崎胜:“肝门部胆管癌的积极手术方法是肝切除术还是局部切除术?”123・2(1998)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
17
    Molecular mechanisms of tumorigenesis of enteric and pancreatic neuroendocrine tumor and development of new molecular targeting therapy.
    • 批准号:
      23659638
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      MIYAZAKI Masaru
    • 依托单位:
    Increased circulating cell signaling phosphoproteins in sera are useful for early detection and the tailor-made therapy for pancreatic and biliary duct cancer patients.
    • 批准号:
      21390372
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.56万
    • 财政年份:
      2009
    • 负责人:
      MIYAZAKI Masaru
    • 依托单位:
    Clarification of pathogenesis and development of therapeutic strategy for small-for size syndrome after major hepatectomy in biliary tract cancer
    • 批准号:
      17390361
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.11万
    • 财政年份:
      2005
    • 负责人:
      MIYAZAKI Masaru
    • 依托单位:
    Mechanism of Liver Organogenesis and Its Application to Liver
    • 批准号:
      14370376
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.02万
    • 财政年份:
      2002
    • 负责人:
      MIYAZAKI Masaru
    • 依托单位: